{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=3", "query": { "intervention": "Brentuximab vedotin", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 123, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Brentuximab+vedotin&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T20:15:04.189Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03007030", "title": "Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CD30-Positive Neoplastic Cells Present", "Malignant Mesothelioma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2017-04-05", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03007030" }, { "nct_id": "NCT01712490", "title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "bleomycin", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1334, "start_date": "2012-11-09", "completion_date": "2026-02-02", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712490" }, { "nct_id": "NCT01393717", "title": "Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": null, "sex": "ALL", "summary": "11 Years and older" }, "enrollment_count": 57, "start_date": "2011-10-20", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01393717" }, { "nct_id": "NCT01830777", "title": "Brentuximab Vedotin + Re-induction Chemotherapy for AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2013-05", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2020-04-14", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830777" }, { "nct_id": "NCT02254239", "title": "Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2016-02-04", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254239" }, { "nct_id": "NCT01476410", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage IV Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "DNA analysis", "type": "GENETIC" }, { "name": "RNA analysis", "type": "GENETIC" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polymorphism analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC", "RADIATION", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 49, "start_date": "2011-11", "completion_date": "2020-05-26", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 7, "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01476410" }, { "nct_id": "NCT03587844", "title": "Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycosis Fungoides", "Lymphomatoid Papulosis", "Sezary Syndrome" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2018-07-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 8, "location_summary": "Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587844" }, { "nct_id": "NCT02086604", "title": "Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2014-09-18", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 2, "location_summary": "St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02086604" }, { "nct_id": "NCT02734771", "title": "A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick Reagan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 24, "start_date": "2016-06", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 2, "location_summary": "Rochester, New York • Charlottesville, Virginia", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734771" }, { "nct_id": "NCT03013933", "title": "Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Hodgkin Lymphoma", "Refractory Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Verapamil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 29, "start_date": "2017-05-03", "completion_date": "2022-05-24", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-02T20:15:04.189Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013933" } ] }